The primary analysis included 186 subjects who received the therapy and 139 subjects who were given a placebo.
Denali’s failure on Monday continues biopharma’s losing streak against amyotrophic lateral sclerosis. PTC Therapeutics and ...
AbbVie, Calico and Denali Therapeutics’ hopes of treating amyotrophic lateral sclerosis (ALS) by targeting eIF2B have all ...
Alphabet is the mother company of Google. Google’s (GOOGL) anti-aging company Calico released disappointing trial results of ...
Denali Therapeutics' DNL343 fails to slow ALS progression in phase 2/3 trial but shows safety and offers insights for future ...
Primary endpoint of overall function (ALSFRS-R) and survival, and key secondary endpoints of muscle strength and respiratory function, were not ...
A clinical trial evaluating the drug fosigotifator in patients with amyotrophic lateral sclerosis has failed to meet its primary endpoint, according to topline results from the Healey ALS platform ...
Announcing a new publication for Acta Materia Medica journal. Complex biological mechanisms and unidentified therapeutic targets for amyotrophic lateral sclerosis (ALS) significantly hinder the develo ...
EST Denali falls 9% to $18 afteramyotrophic lateral sclerosis study missDon't Miss Our New Year's Offers:Discover the latest stocks ...
Synchron announced today that it expanded its partnership with Team Gleason to raise awareness for its brain-computer ...
Central Nervous System Disorders is under clinical development by Neuroplast and currently in Phase I for Amyotrophic Lateral Sclerosis.